New York, USA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Global Antacids Market to Cross ~USD 9 Billion Mark by 2030 | DelveInsight The rising need for antacids is primarily driven by key factors such as the growing incidence of gastroesophageal reflux disease, heartburn, indigestion, and other digestive issues. Additionally, increasing awareness about GERD and acid-related conditions is expected to continue throughout the forecast period from 2024 to 2030.
DelveInsight’s Antacids Market Insights report provides the current and forecast market analysis, individual leading antacids companies’ market shares, challenges, antacids market drivers, barriers, trends, and key market antacids companies in the market. Key Takeaways from the Antacids Market Report As per DelveInsight estimates, North America is anticipated to dominate the global antacids market during the forecast period. In the indication segment of the Antacids market, the arthritis category had a significant revenue share in 2023.
Notable antacids companies such as Bionova, Bayer AG, Haleon, Johnson & Johnson Services Inc., Sanofi, Pfizer Limited, Reckitt Benckiser Group PLC, GSK plc, Novartis AG, Takeda Pharmaceutical Company Limited, Abbott, WellSpring Pharmaceutical Corporation., SPI Pharma, AstraZeneca, Cipla, Phantom Pharmaceuticals, Procter & Gamble, McNeil Consumer Pharmaceuticals Company, Sun Pharmaceutical Industries Ltd.
, Lupin, and several others, are currently operating in the antacids market. In November 202.
